Treatment of Primary Immunodeficiency (PID)
The cornerstone of PID treatment depends on the specific defect: immunoglobulin replacement therapy for antibody deficiencies, hematopoietic stem cell transplantation (HSCT) for severe combined immunodeficiency (SCID), aggressive antimicrobial therapy for all types, and antimicrobial prophylaxis tailored to the specific immune defect. 1
Immediate Actions After Diagnosis
Early diagnosis and rapid initiation of therapy are critical—delays lead to permanent organ damage (bronchiectasis, bronchiolitis obliterans) or death from overwhelming infection. 1 Once PID is diagnosed, proceed immediately with preventive and/or replacement therapy rather than waiting for complications to develop.
Treatment by PID Category
Antibody Deficiency Disorders (Most Common PIDs)
Immunoglobulin replacement therapy is indicated for all disorders with significantly impaired antibody production, including X-linked agammaglobulinemia (XLA), common variable immunodeficiency (CVID), and combined defects with antibody impairment. 1 This therapy is well-documented to reduce serious bacterial infections.
IgG Replacement Specifics:
- Route selection: Either intravenous (IVIG every 2-4 weeks) or subcutaneous (SCIG) administration is effective
- IgA deficiency is NOT a contraindication to IgG therapy when IgG levels are also low—anaphylaxis risk is extremely rare, and some patients who reacted to IVIG tolerate SCIG 1
- Avoid permanent central venous catheters solely for IVIG—use SCIG instead for difficult venous access 1
Monitoring Requirements:
Monitor IgG trough levels, blood cell counts, and serum chemistry every 6-12 months minimum (more frequently in growing children). 1 Adjust dosing based on:
- Trough IgG levels in relation to clinical response
- Frequency of breakthrough infections
- Growth/weight changes
- Enteric losses or increased metabolism
Severe Combined Immunodeficiency (SCID)
HSCT is the definitive treatment for SCID and must be performed as early as possible—outcomes are significantly better when transplantation occurs before 3.5 months of age (95% vs 76% survival) and ideally within the neonatal period. 1
Supportive Care for SCID:
- IgG replacement therapy until B-cell function is restored post-HSCT 1
- PCP prophylaxis is mandatory: Trimethoprim-sulfamethoxazole (5 mg/kg/day trimethoprim orally 3 times per week) is preferred; alternatives include pentamidine (5 mg/kg every 4 weeks), dapsone (1 mg/kg/day), or atovaquone (30 mg/kg/day) 1
- Protective isolation from infectious exposures and large crowds 1
- Only irradiated, CMV-negative, lymphocyte-depleted blood products 1
Antimicrobial Management
Acute Infections:
Use aggressive and prolonged antimicrobial therapy—standard doses and durations are inadequate in immunocompromised hosts. Consider early combined therapy and extended courses. 1
Prophylaxis:
Short- or long-term antimicrobial prophylaxis should be considered based on the specific defect. 1
For Bacterial Respiratory Tract Infections:
Common regimens include 1:
- Amoxicillin: 10-20 mg/kg daily or twice daily (children); 500-1,000 mg daily or twice daily (adults)
- Trimethoprim-sulfamethoxazole: 5 mg/kg daily or twice daily (children); 160 mg daily or twice daily (adults)
- Azithromycin: 10 mg/kg weekly or 5 mg/kg every other day (children); 500 mg weekly or 250 mg every other day (adults)
For Specific T-Cell Defects:
Patients with severe T-cell deficiency require prophylaxis for:
- Pneumocystis jirovecii (as above)
- Certain viral infections (varicella, RSV)
- Fungal infections when indicated
CD40 and CD40L deficiencies require PCP prophylaxis regardless of T-cell numbers. 1
Disease-Specific Considerations
Common Variable Immunodeficiency (CVID):
Manage aggressively with antimicrobials, IgG replacement, and careful pulmonary monitoring. 1 Many patients require chronic antibiotic prophylaxis even with adequate IgG replacement, particularly those with frequent bronchitis or established bronchiectasis.
Monitor for complications:
- Gastrointestinal disease (20-25% prevalence): chronic gastritis, inflammatory bowel disease, enteropathy
- Autoimmune diseases (20% prevalence): cytopenias most common
- Lymphoproliferative disease and malignancy
- Granulomatous and lymphocytic interstitial lung disease (GLILD) in ~10%
Gene Therapy:
Available for specific conditions like ADA deficiency, with no reported leukemia cases (unlike earlier SCID gene therapy approaches). 1
Critical Pitfalls to Avoid
- Delaying definitive therapy in SCID—every week matters for survival and long-term outcomes
- Inadequate antimicrobial courses—immunodeficient patients need longer, more aggressive treatment
- Placing central lines for IVIG alone—infection risk outweighs benefit when SCIG is available
- Withholding IgG therapy due to IgA deficiency—the anaphylaxis risk is extremely small
- Failing to monitor for non-infectious complications in CVID—autoimmunity, malignancy, and organ damage require surveillance